34 results on '"Moliterno, David"'
Search Results
2. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
3. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial
4. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
5. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography
6. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry
7. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
8. Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study
9. Heparin-induced thrombocytopenia and cardiovascular diseases
10. Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
11. The relation of renal function to ischemic and bleeding outcomes with 2 differenct glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial
12. Acute ischemic heart disease: are we appropriately triaging patients with unstable angina?
13. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes
14. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices
15. Angioplasty, inglammation, and antiplatalet agents
16. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
17. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
18. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy
19. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT
20. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine
21. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study
22. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study
23. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials
24. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes
25. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry
26. Bedside activated partial thromboplastin time monitoring: just a matter of time?
27. Are we appropriately triaging patients with unstable angina?
28. TIMI flow and surrogate end points: what you see is not always what you get
29. Diabetes and percutaneous coronary intervention: The sweet smell of success?
30. Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction
31. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial
32. Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
33. Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction
34. Peripartum myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.